Bristol Myers Squibb gains U.S. Food and Drug Administration and European Medicines Agency approvals, expanding Opdivo use in Hodgkin lymphoma
Bristol Myers Squibb has announced significant regulatory milestones that mark a major advancement in the treatment landscape for classical Hodgkin lymphoma (cHL). The company revealed that its immunotherapy drug Opdivo (nivolumab) has received new approvals in both the United States and the European Union, expanding its use across different patient populations and disease stages. These approvals represent an important shift toward immunotherapy-based combinations as a standard of care in cHL.
In the United States, the U.S. Food and Drug Administration has approved Opdivo in combination with the chemotherapy regimen consisting of doxorubicin, vinblastine, and dacarbazine (commonly referred to as AVD). This combination is now indicated for adult and pediatric patients aged 12 years and older who are newly diagnosed with Stage III or Stage IV classical Hodgkin lymphoma. Notably, this marks the first time an immunotherapy-based combination has been approved for frontline treatment in this patient group, signaling a paradigm shift in how advanced cHL is managed.
Meanwhile, in Europe, the European Commission has granted approval for Opdivo in combination with brentuximab vedotin. This regimen is intended for pediatric patients aged 5 years and older, adolescents, and young adults up to 30 years of age who have relapsed or refractory cHL after at least one prior line of therapy. This approval establishes another first, as it introduces an immunotherapy-based combination option for certain patients whose disease has returned or failed to respond to earlier treatment.
These dual approvals underscore a transformative moment in the treatment of classical Hodgkin lymphoma. According to company leadership, the advancements reflect a long-standing commitment to improving outcomes and expanding therapeutic options for patients across different stages of disease. The introduction of Opdivo-based combinations in both frontline and relapsed settings highlights the growing role of immunotherapy in hematologic cancers.
The U.S. approval is supported by data from the Phase 3 SWOG 1826 (CA209-8UT) clinical trial. This study evaluated the efficacy and safety of Opdivo in combination with AVD in patients with previously untreated Stage III or IV cHL. The results demonstrated a substantial improvement in progression-free survival (PFS), which was the primary endpoint of the study. Specifically, the trial showed a 58% reduction in the risk of disease progression or death compared to the standard-of-care regimen that includes brentuximab vedotin plus AVD.
With a median follow-up of 13.7 months in the intention-to-treat population, patients receiving the Opdivo combination experienced significantly better disease control. At a longer median follow-up of 36.7 months, overall survival (OS) data showed that the median OS had not yet been reached in either treatment group. However, fewer deaths were observed in the Opdivo plus AVD arm compared to the comparator arm, further supporting the clinical benefit of the immunotherapy-based regimen.
In parallel, the European approval is based on findings from the Phase 2 CheckMate-744 (CA209744) study. This trial assessed Opdivo in combination with brentuximab vedotin in patients with relapsed or refractory cHL. The study demonstrated promising efficacy in a population with limited treatment options, reinforcing the potential of immunotherapy combinations to address unmet medical needs in both pediatric and young adult patients.
Experts in the field of hematology have highlighted the significance of these findings. Historically, treatment strategies for classical Hodgkin lymphoma have been associated with considerable challenges, including toxicity, relapse risk, and long-term complications. The introduction of nivolumab-based combinations offers a new approach that leverages the immune system to target cancer cells more effectively while potentially improving tolerability.
Beyond efficacy, safety remains a critical consideration. Opdivo, as an immune checkpoint inhibitor, is associated with a range of immune-mediated adverse reactions. These can include serious and potentially fatal conditions such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions. Infusion-related reactions and complications related to allogeneic hematopoietic stem cell transplantation (HSCT) have also been reported. Additionally, there are warnings regarding embryo-fetal toxicity and increased mortality when Opdivo is combined with certain agents in multiple myeloma, outside of controlled clinical trials.
Data from the SWOG 1826 study provide further insight into the safety profile of the Opdivo plus AVD regimen. Serious adverse reactions were reported in 39% of patients receiving the combination therapy. The most common serious events included peripheral neuropathy, neutropenia, fever, febrile neutropenia, and nausea. Fatal adverse reactions were rare, occurring in 0.6% of patients, with sepsis identified as the cause in all reported cases.
In terms of overall side effects, the most frequently observed adverse events included nausea, neutropenia, fatigue, anemia, constipation, leukopenia, musculoskeletal pain, elevated liver enzymes, vomiting, and stomatitis. While these side effects are consistent with known profiles of chemotherapy and immunotherapy, careful monitoring and management are essential to ensure patient safety.
The broader impact of these approvals extends beyond clinical outcomes. For patients and their families, the availability of new treatment options brings renewed hope and confidence in managing the disease. Advocacy groups and medical professionals alike emphasize that each new therapy contributes to incremental progress in improving survival rates and quality of life for individuals living with Hodgkin lymphoma.
Importantly, regulatory evaluation is ongoing in other regions. A submission based on the SWOG 1826 study is currently under review by the European Medicines Agency, which could potentially expand access to this frontline immunotherapy combination across additional European markets.
In conclusion, the recent approvals of Opdivo-based combinations in both the U.S. and EU represent a major milestone in the evolution of classical Hodgkin lymphoma treatment. By integrating immunotherapy into both initial and relapsed treatment settings, these developments are redefining standards of care and offering new possibilities for patients across age groups. As research continues and additional data emerge, the role of immunotherapy in hematologic malignancies is expected to expand further, paving the way for more personalized and effective treatment strategies.
About SWOG 1826 (CA2098UT)
SWOG 1826, also known as CA2098UT, is a randomized, multicenter, Phase 3 study evaluating Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric (12 years and older) patients with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL).3 The study is designed to assess progression-free survival as the primary endpoint, with key secondary endpoints that include overall survival and other measures of efficacy and safety.3 The SWOG 1826 study is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under a Cooperative Research and Development Agreement with Bristol Myers Squibb and conducted in the NCI National Clinical Trials Network (NCTN) led by the SWOG Cancer Research Network in collaboration with the Children’s Oncology Group (COG).3 It is the largest cHL study conducted in the NCTN.3 Bristol Myers Squibb co-sponsored the study and supplied Opdivo to the NCI through a Cooperative Research and Development agreement.3
